Related Experiment Video

Updated: Jun 30, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Targeted suppression of MCT-1 attenuates the malignant phenotype through a translational mechanism

Krystyna Mazan-Mamczarz1, Patrick Hagner, Bojie Dai

  • 1University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA.

Leukemia Research
|October 1, 2008
PubMed

Insights

Targeting the MCT-1 oncogene, crucial in non-Hodgkin's lymphoma, with a PUA-domain mutant protein reduced tumor growth and increased cancer cell death. This approach offers a promising therapeutic strategy for lymphoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The MCT-1 oncogene is highly expressed in certain non-Hodgkin's lymphomas.
  • MCT-1 interacts with the cap complex via its PUA domain, recruiting DENR to promote translation initiation of cancer-related mRNAs.

Purpose of the Study:

  • To investigate the role of the MCT-1 PUA domain in lymphomagenesis.
  • To determine if a PUA-domain mutant protein can attenuate the malignant phenotype of lymphoma cells.

Main Methods:

  • Generation and expression of a PUA-domain mutant MCT-1 protein in human lymphoma cell lines.
  • Assessment of anchorage-independent growth and apoptosis susceptibility.
  • Analysis of the translational profile in cells expressing the mutant protein.

Main Results:

  • Expression of the PUA-domain mutant protein reduced anchorage-independent growth.
  • Cells expressing the mutant protein showed increased susceptibility to apoptosis.
  • An altered translational profile was observed in cells with the mutant protein.

Conclusions:

  • The MCT-1 oncogene plays a significant role in lymphomagenesis.
  • Targeting the MCT-1 PUA domain is a viable strategy for developing novel lymphoma therapeutics.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...